Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Clarify Pharma PLC - investment vehicle specialising in biotech and life sciences companies - Reports pretax loss in the six months to May 31 of £313,000 widened from £297,000 the year before. No revenue was disclosed. Loss per share totaled £0.11 compared to £0.09 before. Sees opportunities for investing in companies with the required expertise and potential to become pioneers in the market. Notes psychedelic assisted therapy is in its earliest days of development, particularly in the UK.
Current stock price: 0.70 pence
12-month change: down 36%
Copyright 2023 Alliance News Ltd. All Rights Reserved.